Solid Bio Posts $53.9M Q3 Loss, Sets Late-Q4 FDA Meeting on Duchenne Gene Therapy
SLDB sits 72% above its 52-week low of $3.79.
Summary
Solid Biosciences reported a $53.9 million net loss for Q3 2026, wider than the $45.8 million loss a year ago, as R&D rose to $43.6 million and G&A jumped to $14.1 million. Cash, equivalents and available-for-sale securities stood at $348.9 million at September 30, up from $187.9 million at year-end 2025, and management says that funds operations into the first half of 2028. The clinical update is the part that matters: SGT-003 has been generally well tolerated across 53 participants dosed in the Phase 1/2 INSPIRE DUCHENNE trial as of November 3, and the company has scheduled a Type C meeting with the FDA late in Q4 2026 to discuss the preliminary data package and a potential accelerated approval pathway. The Phase 3 IMPACT DUCHENNE trial began dosing in Q2 2026 and is still enrolling. In Friedreich's ataxia, five participants have been dosed in the Phase 1b FALCON trial with no treatment-related serious adverse events, SGT-212 picked up EU Orphan designation in October, and initial data are expected in Q1 2027. The FDA meeting minutes and the Q1 2027 FALCON readout are the next hard checkpoints.
At the time of this announcement, SLDB was trading at $6.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $699.1M. The 52-week trading range was $3.79 to $11.45. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.